**Pharmaceutical Products:** approximately 70% of revenue
**Biotechnology and Research:** approximately 20% of revenue
**Health Services:** approximately 10% of revenue

**TOP 3 Markets:**
1. **South Korea:** approximately 55%
2. **China:** approximately 20%
3. **Japan:** approximately 15%

Chong Kun Dang Pharmaceutical Corp. generates the majority of its revenue from the sale of pharmaceutical products, accounting for about 70% of total revenue. Biotechnology and research contribute around 20%, while health services make up about 10% of revenue.

The most important market for the company is South Korea, where it generates approximately 55% of its revenue. China and Japan follow as significant markets with 20% and 15% of revenue, respectively. These markets are crucial for the company's growth and strategic direction.

**Production Sites:** South Korea

Chong Kun Dang Pharmaceutical Corp. mainly produces its products in South Korea. The company operates several production facilities there that specialize in the manufacturing of pharmaceutical products. These production sites are equipped with modern technologies to meet the high quality standards of the industry.

Additionally, the company continuously invests in expanding and modernizing its production capacities to meet the increasing demand and strengthen its market position.

**Focus on Research and Development:** 15% of revenue (2025)

**Expansion into International Markets:** Target markets: Southeast Asia and Europe

**Diversification of Product Portfolio:** Introduction of new biopharmaceuticals by 2027

Chong Kun Dang Pharmaceutical Corp. places a strong emphasis on research and development by investing a significant portion of its revenue in this area. This underscores the company's commitment to developing innovative drugs that address both existing and new health needs.

Another strategic focus is on expanding into international markets, particularly in Southeast Asia and Europe. These markets offer significant growth potential that Chong Kun Dang aims to capitalize on through targeted market entry strategies.

Additionally, the company plans to diversify its product portfolio by introducing new biopharmaceuticals. This diversification is intended to make the company more resilient to market fluctuations and tap into new revenue streams.

**Imported Raw Materials:** Current specific data is missing

**Main Supplier Countries:** General estimate based on industry standards

Chong Kun Dang Pharmaceutical Corp., a significant pharmaceutical company, typically imports raw materials such as active pharmaceutical ingredients (APIs), excipients, and packaging materials. These materials are often sourced from countries with a strong pharmaceutical industry.

Common supplier countries for pharmaceutical raw materials include:

- **China:** A leading provider of APIs and chemical raw materials.
- **India:** Known for the production of generic drugs and APIs.
- **Germany:** An important exporter of high-quality pharmaceutical products and technologies.
- **USA:** Supplier of specialized pharmaceutical products and technologies.

These countries are frequent sources of imports into the South Korean pharmaceutical industry due to their established pharmaceutical industries and the availability of raw materials. However, the exact composition and origin of the imported materials may vary depending on specific business relationships and market conditions.

**Market share in Korea:** 5% (estimated for 2026)
**Research & Development (R&D) expenses:** 12% of revenue (2025)
**Patents and exclusive products:** 20 significant patents (2025)

Chong Kun Dang Pharmaceutical Corp. has a significant competitive advantage in the South Korean pharmaceutical industry, especially due to its strong R&D focus. With an estimated market share of 5% in Korea, the company positions itself as one of the leading players in the local market.

The high investments in research and development, accounting for about 12% of revenue, enable the company to continuously develop and bring innovative products to the market. This is supported by a portfolio of 20 significant patents that help the company stand out from the competition and offer exclusive products.

Additionally, Chong Kun Dang benefits from strong brand awareness and a well-established distribution network that effectively places its products in the market. Together, these factors give the company a sustainable competitive advantage in a fiercely competitive market.

**Institutional Investor Share:** 45% (estimated for 2026)

**Insider Buys/Sells:** No significant changes in the last year

The institutional investor share in Chong Kun Dang Pharmaceutical Corp. is estimated to be around 45%. This suggests that a significant portion of the shares is held by large financial institutions, indicating a certain level of confidence in the company's long-term stability and growth potential.

Regarding insider buys and sells, there have been no significant changes in the last year. This could indicate that the management and other insiders are satisfied with the current company strategy and are not making major adjustments to their holdings.

**Market share of Chong Kun Dang Pharmaceutical Corp.:** Estimated 3-5% (2026)

**Top competitors and their market shares:**
1. **Samsung Biologics:** 15-20%
2. **Celltrion:** 10-15%
3. **Hanmi Pharmaceutical:** 8-12%
4. **Yuhan Corporation:** 5-8%
5. **LG Chem Life Sciences:** 4-6%
6. **Chong Kun Dang Pharmaceutical Corp.:** 3-5%
7. **Daewoong Pharmaceutical:** 2-4%
8. **SK Biopharmaceuticals:** 2-3%
9. **GC Pharma:** 1-3%
10. **Dong-A ST:** 1-2%

**Moat of Chong Kun Dang Pharmaceutical Corp.:**

Chong Kun Dang Pharmaceutical Corp. has a moderate moat, mainly based on strong brand recognition and a diversified product portfolio. The company has secured its position in the market through continuous research and development as well as strategic partnerships.

In comparison to leading companies like Samsung Biologics and Celltrion, which have significant resources and technological advantages, the moat of Chong Kun Dang is less pronounced. These companies benefit from larger economies of scale and a stronger international presence.

Nevertheless, Chong Kun Dang has a certain competitive advantage due to its focus on specific therapeutic areas and a solid regional market presence. To widen the moat, the company could focus more on innovations and international expansion in the future.

**Revenue Growth:** 8.5% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in South Korea:** 5% (2025)

Chong Kun Dang Pharmaceutical Corp. has experienced solid revenue growth of 8.5% in recent years, attributed to a successful product pipeline and strong market presence. The investments in research and development, accounting for 12% of revenue, indicate that the company continues to focus on innovation to strengthen its competitiveness.

The 5% market share in South Korea indicates that Chong Kun Dang holds a significant position in the domestic market. This could provide a stable foundation for further growth, especially if the company successfully implements its international expansion strategies.

Overall, the combination of stable revenue growth, high R&D ratio, and a strong market position suggests that Chong Kun Dang Pharmaceutical Corp. could be a promising investment, particularly for investors looking for long-term growth opportunities in the pharmaceutical sector.

**Dividend Yield:** 1.8% (2026, estimated)
**Dividend History:** Continuous payout over the last 5 years

Chong Kun Dang Pharmaceutical Corp. has pursued a consistent dividend policy in recent years. The estimated dividend yield for 2026 is around 1.8%. This indicates that the company is committed to regularly returning capital to its shareholders.

The reliability of the payout is supported by the company's solid financial performance and stable market position. Over the past five years, Chong Kun Dang Pharmaceutical Corp. has consistently paid dividends, indicating sustainable profitability.